Merz Launches XEOMIN In Canada
Merz has reported that new XEOMIN (Botulinum neurotoxin type A) is now available in Canada. The drug would be prescribed to patients with Blepharospasm, Cervical Dystonia and Post-Stroke
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.